Daniel Welch

Daniel G.
Welch is currently Chief Executive Officer at Phylaxis Bioscience; Chairman at Ultragenyx Pharmaceutical, Inc. since 2015; Executive Chairman at InCarda Therapeutics, Inc. since 2019; Chairman at Prothena Corp.
Plc since 2024; Executive Chairman at Levo Therapeutics, Inc. since 2018; Chairman at Structure Therapeutics, Inc. since 2022; Chairman at Shanghai ShouTi Biotechnology Co. Ltd.; and Chairman at Kinaset Therapeutics, Inc. starting in 2026.
Former roles include Chairman & Chief Executive Officer at Triangle Pharmaceuticals, Inc. (2002–2003); Chairman, President & Chief Executive Officer at InterMune, Inc. (2008–2015); Chairman at Novartis Gene Therapies, Inc. (2016–2018); Chairman at Nuvation Bio, Inc. (2020–2024); Chairman at Nuvation Bio Operating Co., Inc.; Independent Director at Intercept Pharmaceuticals, Inc. (2015–2021); Independent Director at Hyperion Therapeutics, Inc. (2013–2015); Director at Corium LLC (Massachusetts) (2007–2014); Independent Director at Seagen, Inc. (2007–2023); President-Biopharmaceuticals Division at Elan Corp.
Plc (2000–2002); Executive Partner at Sofinnova Investments, Inc. (2015–2018); Vice President-Worldwide Marketing at Sterling Winthrop, Inc.; Chief Operating Officer & Executive Vice President at Sanofi-Synthelabo, Inc. (1987–2000); Principal at Adria Laboratories; and Partner at Sofinnova Ventures (2015–2018).
Education includes undergraduate studies at the University of Miami and an MBA from The University of North Carolina at Charlotte.